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To examine the association of serum concentrations of
25-hydroxyvitamin D [25(OH)D], interleukin-6 (IL-6), C-reactive




The Longitudinal Aging Study Amsterdam (LASA), a








The respondents were men and women aged 65 and
































 and 3-year incidence of









, 242 (19·0%) of all respondents were frail. Those who




 had higher CRP and lower 25(OH)D levels. Serum
25(OH)D remained associated with frailty after adjustment for
potential confounders with an odd ratios (OR) of 2·60 [95% con-
fidence interval (95% CI) 1·60–4·21] for 25(OH)D < 25 nmol/ l









, 125 respondents (14·1%)









g /ml) (OR 1·69, 95% CI 1·09–2·63) and low 25(OH)D
(OR 2·04, 95% CI 1·01–4·13) were associated with incident frailty.




Low 25(OH)D levels were strongly associated with
prevalent and incident frailty; moderately elevated levels of CRP
were associated with incident frailty.
(Received 9 March 2005; returned for revision 30 March 2005; finally 
 




Frail is a term used to describe an older person at risk for adverse





















and is considered to be a consequence of changes in neuromuscular,








. hypothesized a negative spiral in which inflammation,




However, there is little empirical evidence for the role of endocrine
and inflammatory markers of frailty.
There are several reasons to expect that inflammatory and endo-
crine markers are associated with frailty. First, studies have shown
that the levels of inflammatory markers, such as interleukin-6
(IL-6) and C-reactive protein (CRP), increase with ageing, and that










 Furthermore, vitamin D deficiency
is common in older people, with a gradual decline in levels from































 Interaction between IGF-1 and IL-6 in




Only a few investigators have studied the direct relationship




 Most studies investigat-
ing endocrine and inflammatory markers so far have focused on out-





the relationship between frailty, endocrine markers and inflamma-
tion has been investigated in cross-sectional studies only, which
makes it difficult to draw conclusions on the predictive value of the
endocrine and inflammatory markers for frailty. The aim of this
study was to examine the associations between endocrine and
inflammatory markers and frailty, cross-sectionally and prospec-
tively in the subsequent 3 years in a population-based study of men






The data were collected in the context of the Longitudinal Aging
Study Amsterdam (LASA). LASA is an ongoing multidisciplinary
study on predictors and consequences of changes in physical,
cognitive, emotional and social functioning in older people in the
Netherlands. A random sample stratified by age and gender according
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to expected mortality after 5 years was drawn from population
registers of 11 municipalities in three geographical areas in the
Netherlands. At each cycle, data were collected in a face-to-face
main interview, carried out in the subjects’ home or institutional
residence, by specially trained interviewers, followed by a medical





 (see also http://ssg.scw.vu.nl/ lasa/). The
Medical Ethics Committee of the VU University Medical Centre
approved the study and informed consent was obtained from all
respondents.
The sample for this study consisted of respondents who parti-





 (1995/1996) and were asked to participate in a medical interview





 = 1720). Of the 1720 respondents who were eligible for
the medical interview, 1509 participated (87·7%). Blood samples
were obtained from 1321 respondents. In 1285 of these respondents
all four serum markers were determined (74·7%). For the cross-
sectional analyses, 14 respondents were excluded because of missing
covariates, leaving a sample of 1271 respondents. The nonresponders
at baseline (1995/1996) were older, had more cognitive problems and
chronic disease, and a lower education level. There were no sex
differences in nonresponse.
For the prospective analyses with 3 years of follow-up, 231 of the
1271 respondents were lost to follow-up; 159 respondents died, 12
respondents refused, 11 were not able to participate due to physical
or cognitive problems, six respondents could not be contacted and
43 respondents were excluded because no information on the frailty
indicators was available. Of the remaining 1040 respondents for the
prospective analyses, the respondents who were frail at baseline were
excluded from the study on the effect of serum endocrine and
inflammatory markers on incident frailty, leaving a sample of 885
respondents. Those lost to follow-up more often had higher levels
of IL-6 and CRP, and lower levels of IGF-1 and 25(OH)D. Those lost
to follow-up were older, had more cognitive problems, more depres-
sive symptoms, more chronic diseases and more frailty markers
present at baseline.
 
Serum endocrine and inflammatory markers
 
Morning blood samples were obtained in 1995/1996. The particip-
ants were allowed only tea and toast. The samples were centrifuged









Serum 25(OH)D was measured according to a competitive bind-
ing protein assay (Nichols Diagnostics, San Capistrano, CA, USA).
IGF-1 was determined by immunoradiometric assay after extraction
(DSL, Webster, TX, USA). These analyses were carried out at the
Endocrine Laboratory of the VU University Medical Centre, Amsterdam.
The serum concentrations of CRP and IL-6 were determined
using a sensitive enzyme-linked immunosorbent assay (ELISA) at
Sanquin Research, Amsterdam. The IL-6 ELISA was obtained from
the Business Unit Immune Reagents of Sanquin, and performed
according to the manufacturer’s instructions. CRP levels were meas-
ured with a sandwich-type ELISA in which polyclonal rabbit anti-
CRP antibodies were used as catching antibodies and a biotinylated
monoclonal antibody (mAb) against CRP (CLB anti-CRP-2) as the
detecting antibody. CRP and IL-6 were measured in duplicate, and
averages were reported.
The detection limit was 10 nmol/l for 25(OH)D, 1 nmol/l for IGF-1,
0·8 ng/ml for CRP, and 5·0 pg/ml for IL-6. Recombinant IL-6, purified
CRP and pooled human plasma were used as standards in the respec-
tive assays. The interassay coefficient of variation (CV) was < 4·2% for




Nine frailty indicators were used to determine frailty. Both physical




 for an exten-

























 [Mini-mental State Examina-






poor distant vision and hearing problems
 












low sense of mastery
 
 (short version of the Pearlin and Schooler mas-
























 (LASA Physical Activity Questionnaire,





The definition of frailty in this study was the presence of three
or more out of nine frailty indicators. Also the number of frailty




The analyses were adjusted for age, sex, education, season of blood
sampling, use of prescribed anti-inflammatory drugs [nonsteroidal
anti-inflammatory drugs (NSAIDs), aspirin and corticosteroids],
use of oestrogens, smoking status, alcohol consumption, obesity,
high-intensity physical activity, levels of PTH and chronic disease.
The presence of chronic disease, use of oestrogens, smoking, obesity
and alcohol consumption increase the levels of inflammatory markers




 High-intensity physical activity










 autumn/winter) because the serum concentra-















 and were therefore included in all analyses.
The respondents were asked about their highest level of education
attained, which was categorized into three categories (low, middle
and high). Serum concentration of PTH was measured by immuno-
radiometric assay (Incstar Corp., Stillwater, MN, USA) and was
used as a continuous variable in the analyses. The interviewers
inspected medication bottles, and the medication was recorded if it
was prescribed by a general practitioner and used in the 2 weeks








 other. Alcohol use was also examined with more categories
(moderate and excessive drinking), but preliminary analyses showed
that these groups did not differ in their associations with frailty and








. High-intensity physical activity (yes/no) was based on
 


















 5·0: distance walking, cycling, swimming, dancing, jogging, rowing,
playing tennis, soccer, basketball, volleyball and winter sports. Seven
self-reported chronic diseases were examined: chronic obstructive
pulmonary diseases, cardiac disease (myocardial infarction, arrhy-
thmias, congestive heart failure, angina pectoris and narrowing of
the coronary arteries), peripheral arterial disease, diabetes mellitus,
cerebrovascular accidents, rheumatoid arthritis or osteoarthritis (both
conditions were grouped together because respondents found it
difficult to differentiate between them) and cancer. These chronic
diseases are the most frequent in the Dutch older population with
a prevalence of at least 5%. Agreement between respondents’ self-
reported data and data from the general practitioner has been shown









Serum 25(OH)D was categorized into three groups: < 25, 25–50 and




 The highest group was the reference group. IGF-1 was
dichotomized at the lowest 10% (below 7·7 nmol/ l) as these levels





dichotomized at the detection limit (5 pg/ml), with low as the ref-
erence group. Because of the large numbers of respondents below the
detection limit it was not possible to divide IL-6 into more categories.




































-tests were performed to assess differences
between those who were frail and those who were not frail at base-
line. For the examination of the cross-sectional association, logistic
regression analyses were performed for each of the endocrine and
inflammatory markers with the presence of frailty as the outcome
measure. The first model included only the single serum markers,
sex and age. In the second model, season of blood sampling (only
for 25(OH)D), use of anti-inflammatory drugs (only for CRP and
IL-6), smoking status, alcohol use, oestrogen use, obesity (only for
CRP and IL-6) and physical activity (only for CRP and IL-6) were
included. For all serum markers, the interaction with sex and the





the final model, chronic disease and PTH (PTH only for 25(OH)D)
were added, to study whether PTH and chronic diseases mediated
the relationship between endocrine and inflammatory markers and
frailty. All serum markers were finally included in a single model to
study their associations with frailty adjusted for each other.
For the examination of the prospective association, logistic regres-
sion analyses were performed to study whether serum markers pre-
dicted incident frailty. The consecutive logistic regression models
were similar to those of the cross-sectional analyses.
As an additional outcome variable, the total number of frailty
indicators was used and associations were tested with multinomial
logistic regression analysis. The group without any frailty indicators
was the reference group. For the cross-sectional analysis, respondents
with four or more frailty indicators were grouped together because
of small numbers. In the prospective analysis, respondents with three
or more frailty indicators were grouped together because of small
numbers. Analyses were adjusted for baseline number of frailty in-




Characteristics of the sample
 
There were 242 (19·0%) frail respondents at baseline (1995/1996).




74·5 years), had more chronic disease, and more often had low serum
concentration of 25(OH)D and higher serum concentration of CRP
(Table 1, left segment). Frail respondents also more often had a lower
level of education, higher BMI, higher serum PTH, and smoked and
used alcohol less often.
One hundred and twenty-five respondents (14·1%) who were not




, 1998/1999). They were
older, and more often had lower serum concentrations of 25(OH)D
and IGF-1 and higher serum concentrations of CRP at baseline
(Table 1, right segment).
 
Cross-sectional analyses of frailty
 
Low serum 25(OH)D concentrations were significantly associated
with frailty when adjusting for sex and age (model 1, Table 2). Com-
pared to high serum 25(OH)D, the odds ratio (OR) for low serum
25(OH)D was 2·95 [95% confidence interval (95% CI) 1·87–4·65],
and 1·85 (95% CI 1·31–2·60) for moderately low serum 25(OH)D.
The ORs decreased to 2·60 (95% CI 1·60–4·21) and 1·72 (95% CI
1·19–2·47) (model 3) when adjusting for all confounders. There was
no significant cross-sectional association of CRP, IGF-1 and IL-6
with frailty when adjusting for all confounders. When the serum
markers were adjusted for each other, the results were similar. There
was no interaction between the serum markers or between the serum
markers and sex cross-sectionally.
 
Prospective analyses of frailty
 










serum concentrations of CRP when adjusting for sex and age (Table 3).
The OR decreased to 1·69 (95% CI 1·09–2·63) when adjusting for
all confounders. Low serum 25(OH)D was also significantly associ-




high serum 25(OH)D when adjusting for all confounders. When all
biological markers were included in a model, the OR of serum CRP
did not change but the OR for low serum 25(OH)D changed to
1·90 (95% CI 0·92–3·95). There was no significant prospective asso-
ciation of serum IGF-1 and serum IL-6 with incident frailty when
adjusting for all confounders. Again, there was no interaction between
the serum markers or between the serum markers and sex.
 
Additional analyses of number of frailty indicators
 
From cross-sectional analyses (Table 4, left segment), it can be seen


















three and four or more frailty indicators (Fig. 1). Moderate levels of
serum 25(OH)D were associated with three frailty indicators only.
Low serum IGF-1 was associated with four or more frailty markers.
From the prospective multinomial logistic regression analyses
(Table 4, right segment), it can be seen that low serum 25(OH)D was
associated with one and three or more frailty indicators (Fig. 1). Fur-
thermore, moderately elevated serum CRP was associated with three
or more frailty indicators. The results did not change when all serum




To our knowledge, this study is the first to examine the association
of four endocrine and inflammatory markers with prevalent and
incident frailty in a large population-based sample. Low serum con-
centrations of 25(OH)D were associated with prevalent and incident
frailty with a clear dose–response relationship. In the prospective





dicted the incidence of frailty. These associations were independent
of each other and independent of the effects of smoking, drinking,
high BMI, intense physical activity, use of anti-inflammatory drugs,
chronic disease and education.
The mechanism explaining the relationship between low levels of
25(OH)D and frailty is not yet clear. Low 25(OH)D levels have been





 In a previous report based on LASA, low 25(OH)D levels were




 showing that both
vitamin D deficiency and insufficiency may cause loss of muscle
mass and strength. As a result of loss of muscle mass and muscle
weakness, older persons may become less active, accelerating the
frailty process. A reverse pathway is also possible: older people often
may not go outside and may be physically inactive as a consequence
of their frail health, resulting in very low sunlight exposure, which
subsequently causes vitamin D deficiency. However, this pathway is
not supported by our longitudinal analyses. Thus the first pathway
seems the most likely. Although the LASA is a prospective cohort
study, as in most prospective cohort studies it remains difficult
to investigate causal relationships. Randomized clinical trials are




Cross-sectional analyses Prospective analyses
Not frail at 
T1 N = 1029
Frail at 




T2 N = 760
Frail at 
T2 N = 125
Overall
P-value
Endocrine and inflammatory markers
25(OH)D < 25 nmol/ l 85 (8·3%) 56 (23·2%) 0·000 46 (6·1%) 20 (16·0%) 0·000
25(OH)D 25–50 nmol/ l 355 (34·5%) 116 (47·9%) 254 (33·4%) 51 (40·8%)
25(OH)D > 50 nmol/ l 589 (57·2%) 70 (28·9%) 460 (60·5%) 54 (43·2%)
IGF-1 ≤ 7·7 nmol/ l 97 (9·4%) 33 (13·6%) 0·052 60 (7·9%) 19 (15·2%) 0·008
IL-6 ≥ 5·0 pg/ml 111 (10·8%) 28 (11·6%) 0·725 69 (9·1%) 15 (12·1%) 0·302
CRP < 3·0 µg/ml 525 (51·0%) 95 (39·3%) 0·004 424 (55·8%) 53 (42·4%) 0·006
CRP 3·0–10·0 µg/ml 359 (34·9%) 102 (42·1%) 242 (31·8%) 58 (46·4%)
CRP > 10·0 µg/ml 145 (14·1%) 45 (18·6%) 94 (12·3%) 14 (11·3%)
Number of frailty indicators present at baseline
0 362 (35·2%) 0 0·000 309 (40·7%) 13 (10·4%) 0·000
1 399 (38·8%) 0 303 (39·9%) 43 (34·4%)
2 268 (26·0%) 0 148 (19·5%) 69 (55·2%)
3 0 136 (56·2%) 0 0
4 0 106 (43·8%)
Covariates
Women (%) 498 (48·4%) 151 (62·4%) 0·000 378 (49·7%) 69 (55·2%) 0·258
Mean age (SD) 74·5 (6·3) 79·2 (6·2) 0·000 73·4 (5·9) 78·2 (6·2) 0·000
Low level of education 399 (38·8%) 132 (54·5%) 0·000 277 (36·4%) 57 (45·6%) 0·082
Middle level of education 481 (46·7%) 76 (31·4%) 378 (49·7%) 49 (39·2%)
High level of education 149 (14·5%) 34 (14·0%) 105 (13·8%) 19 (15·2%)
Mean no. chronic diseases (SD) 1·1 (1·0) 1·6 (1·1) 0·000 1·0 (0·9) 1·3 (1·1) 0·002
BMI > 30 kg/m2 196 (19·0%) 62 (25·6%) 0·022 147 (19·3%) 29 (23·2%) 0·317
Mean PTH (pmol/ l) (SD) 3·5 (1·9) 4·2 (2·5) 0·000 3·4 (1·8) 3·6 (1·4) 0·185
High-intensity physical activity 211 (20·5%) 18 (7·4%) 0·000 181 (23·8%) 18 (14·4%) 0·019
Never smoked 339 (33·0%) 111 (45·9%) 0·000 255 (33·6%) 47 (37·6%) 0·376
Ever smoked 690 (67·1%) 131 (54·1%) 505 (66·4%) 78 (62·4%)
No alcohol use 224 (21·8%) 89 (36·8%) 0·000 159 (20·9%) 24 (19·2%) 0·660
Alcohol use 805 (78·2%) 153 (63·2%) 601 (79·1%) 101 (80·8%)
Use of anti-inflammatory drugs 277 (26·9%) 88 (36·4%) 0·003 183 (24·1%) 43 (34·4%) 0·014
Use of oestrogens 9 (0·9%) 4 (1·7%) 0·279 6 (0·8%) 2 (1·6%) 0·375
 













necessary to investigate whether vitamin D supplementation can
prevent frailty. It is known that a low serum 25(OH)D concentration
can be easily corrected by sunlight exposure or vitamin D supple-
mentation of 400–800 IU/day. Supplementation has been shown to
effectively improve vitamin D status, bone mineral density and
muscle strength in older people.13,16 However, no trials have been
performed focusing on new frailty.
In the only other large cross-sectional study investigating the rela-
tionship between frailty and biological serum markers, Walston et al.
found that persons who had CRP levels > 5·77 mg/l had an OR of
3·5 for prevalent frailty, in contrast to our study, which showed no
association between CRP and prevalent frailty.19 However, in our
study, moderately elevated levels of CRP (3–10 µg/ml) were associ-
ated with incident frailty in both men and women after 3 years. With
ageing, the levels of circulating cytokines increase, equivalent to a
low-grade systemic inflammation, but not necessarily to the levels
of acute infections.17 CRP levels above 10 µg/ml are generally asso-
ciated with acute disease. This is supported by our data: the respondents
with the highest CRP levels had more chronic disease, used more
anti-inflammatory drugs, had more frailty indicators present at
Table 2. Odds ratios (with 95%CI) from cross-sectional logistic regression analyses of the association of four serum markers and prevalent frailty (n = 1271)
 
N Serum marker Model 1 Model 2 Model 3 Model 4
1132 IL-6 < 5 pg/ml 1 1 1 1
139 IL-6 ≥ 5 pg/ml 0·98 (0·62–1·57) 0·96 (0·60–1·53) 0·94 (0·58–1·53) 0·75 (0·44–1·27)
620 CRP < 3·0 µg/ml 1 1 1 1
461 CRP 3·0–10·0 µg/ml 1·35 (0·99–1·89) 1·27 (0·91–1·78) 1·20 (0·85–1·69) 1·14 (0·80–1·61)
190 CRP > 10·0 µg/ml 1·64 (1·07–2·50) 1·46 (0·95–2·25) 1·37 (0·88–2·13) 1·37 (0·85–2·19)
141 25(OH)D < 25 nmol/ l 2·95 (1·87–4·65) 3·04 (1·92–4·82) 2·60 (1·60–4·21) 2·55 (1·56 – 4·17)
471 25(OH)D 25–50 nmol/ l 1·85 (1·31–2·62) 1·88 (1·32–2·67) 1·72 (1·19–2·47) 1·66 (1·15 –2·40)
659 25(OH)D > 50 nmol/ l 1 1 1 1
130 IGF-1 ≤ 7·7 nmol/ l 1·02 (0·65–1·60) 0·98 (0·62–1·54) 1·01 (0·64–1·61) 0·88 (0·54–1·41)
1141 IGF-1 > 7·7 nmol/ l 1 1 1 1
Bold text = P < 0·05
Model 1: single endocrine and inflammatory markers, adjustment for age and sex.
Model 2: single endocrine and inflammatory markers, additional adjustment for IL-6 and CRP for education, use of anti-inflammatory drugs, use of oestrogen, 
obesity, physical activity, smoking status, and alcohol consumption. For 25(OH)D, additional adjustment for education, season of blood sampling, smoking 
status and alcohol consumption. For IGF-1, additional adjustment for education, smoking status and alcohol consumption.
Model 3: single endocrine and inflammatory markers, additional adjustment for the self-reported chronic diseases: cardiac disease, peripheral arterial disease, 
diabetes mellitus, arthritic disease, chronic obstructive pulmonary disease, stroke and cancer. For 25(OH)D, additional adjustment for PTH.
Model 4: All endocrine and inflammatory markers in model, additional adjustment for the self-reported chronic diseases: cardiac disease, peripheral arterial 
disease, diabetes mellitus, arthritic disease, chronic obstructive pulmonary disease, stroke and cancer.
Table 3. Odds ratios (with 95% CI) from prospective logistic regression analyses of the association of four serum markers and incident frailty (n = 885)
 
N Serum marker Model 1 Model 2 Model 3 Model 4
801 IL-6 < 5 pg/ml 1 1 1 1
84 IL-6 ≥ 5 pg/ml 1·08 (0·58–2·02) 1·00 (0·53–1·89) 1·03 (0·54–1·97) 0·93 (0·47–1·84)
477 CRP < 3·0 µg/ml 1 1 1 1
300 CRP 3·0–10·0 µg/ml 1·77 (1·15–2·68) 1·72 (1·11–2·65) 1·69 (1·09–2·63) 1·70 (1·09 – 67)
108 CRP > 10·0 µg/ml 1·27 (0·66–2·45) 1·23 (0·63–2·39) 1·17 (0·69–2·31) 1·13 (0·56–2·27)
66 25(OH)D < 25 nmol/ l 1·89 (0·98–3·63) 2·02 (1·03–3·94) 2·04 (1·01–4·13) 1·90 (0·92–3·95)
305 25(OH)D 25–50 nmol/ l 1·14 (0·73–1·77) 1·21 (0·77–1·89) 1·30 (0·82–2·07) 1·24 (0·77–2·00)
514 25(OH)D > 50 nmol/ l 1 1 1 1
79 IGF-1 ≤ 7·7 nmol/ l 1·42 (0·79–2·57) 1·53 (0·84–2·80) 1·47 (0·79–2·72) 1·40 (0·74–2·62)
806 IGF-1 > 7·7 nmol/ l 1 1 1 1
Bold text = P < 0·05
Model 1: single endocrine and inflammatory markers, adjustment for age and sex.
Model 2: single endocrine and inflammatory markers additional adjustment for IL-6 and CRP for education, use of anti-inflammatory drugs, use of oestrogen, 
obesity, physical activity, smoking status, alcohol use. For 25(OH)D, additional adjustment for education, season of blood sampling, smoking status and alcohol 
use. For IGF-1, additional adjustment for education, smoking status and alcohol use.
Model 3: single endocrine and inflammatory markers additional adjustment for the self-reported chronic diseases: cardiac disease, peripheral arterial disease, 
diabetes mellitus, arthritic disease, chronic obstructive pulmonary disease, stroke and cancer. For 25(OH)D, additional adjustment for PTH.
Model 4: All endocrine and inflammatory markers in model, additional adjustment for the self-reported chronic diseases: cardiac disease, peripheral arterial 
disease, diabetes mellitus, arthritic disease, chronic obstructive pulmonary disease, stroke and cancer.
408 M. T. E. Puts et al.
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baseline and were more often lost to follow-up (data not shown).
High CRP levels have been shown to be associated with a high risk
of cardiovascular events and mortality.37 A possible explanation of
why we did not find an association with frailty in subjects with high
levels of CRP, but only in subjects with moderately elevated levels of
CRP, is selective dropout. Nevertheless, the finding that moderately
elevated levels of CRP are associated with incident frailty is in agree-
ment with the hypothesis that frailty is a result of chronic low-grade
inflammation.
In this study, low serum IGF-1 was significantly associated with
the presence of four or more frailty indicators in cross-sectional
multinomial regression analysis. In logistic regression analysis, a ten-
dency for an association between low IGF-1 and frailty was seen. This
finding is in line with reports that IGF-1 is associated with disability
and mobility decline.8,36
In contrast to other studies in which the association between IL-6
and frailty was examined,20,21 we found no association between IL-6
and frailty. A possible explanation for this lack of association is the
high detection limit of our assay. Associations between IL-6 and
health outcomes have been observed at levels far below the detection
limit of our study.22,34
Leng et al. found an inverse relationship between IL-6 and IGF-1,
suggesting an interaction between endocrine and immune function-
ing.21 IL-6 plays an important role in the inflammatory response by
inducing the synthesis of acute-phase proteins, such as CRP, and
inhibiting the synthesis of IGF-1.39 In this study we found no inter-
action between IL-6 and IGF-1. However, this could be the result of
the high detection limit for IL-6, limiting the number of respondents
in which the interaction could be examined. Results from other stud-
ies have shown that vitamin D has important effects on the function
of the immune system.40 Vitamin D deficiency has been shown to
occur in patients with inflammatory bowel disease,41 and vitamin D
status was associated with cancer and autoimmune diseases.42 Studies
in mice have shown that supplementation with vitamin D can protect
Table 4. Odds ratios (with 95% CI) from multinomial logistic regression analysis of the association of single serum markers and the number of frailty indicators 




1 vs. 0* 2 vs. 0* 3 vs. 0* ≥ 4 vs. 0* 1 vs. 0† 2 vs. 0† ≥ 3 vs. 0†
IL-6 < 5 pg/ml 1 1 1 1 1 1 1
IL-6 ≥ 5 pg/ml 0·97 0·99 1·10 0·73 1·28 0·90 1·11
(0·60–1·56) (0·58–1·70) (0·58–2·14) (0·33–1·61) (0·70–2·34) (0·42–1·91) (0·48–2·53)
CRP < 3 µg/ml 1 1 1 1 1 1 1
CRP 3·0–10·0 µg/ml 0·84 0·98 1·30 0·83 1·17 0·98 1·88
(0·58–1·13) (0·67–1·44) (0·81–2·09) (0·48–1·43) (0·79–1·73) (0·60–1·59) (1·08 –3·26)
CRP > 10 µg/ml 0·64 0·84 0·88 1·28 0·94 1·08 1·10
(0·40–1·01) (0·51–1·38) (0·46–1·69) (0·67–2·44) (0·54–1·64) (0·56–2·08) (0·48–2·52)
25(OH)D < 25 nmol/ l 1·22 1·16 2·51 3·37 2·83 1·92 5·05
(0·66–2·24) (0·59–2·26) (1·19–5·30) (1·56–7·29) (1·17–6·84) (0·70–5·23) (1·80 –14·14)
25(OH)D 25–50 nmol/ l 1·00 1·26 2·06 1·56 1·04 0·94 1·27
(0·71–1·40) (0·86–1·84) (1·25–3·41) (0·88–2·79) (0·70–1·54) (0·58–1·50) (0·73–2·24)
25(OH)D > 50 nmol/ l 1 1 1 1 1 1 1
IGF-1 ≤ 7·7 nmol/ l 1·58 1·52 0·96 2·15 1·29 1·07 1·72
(0·91–2·76) (0·83–2·80) (0·44–2·07) (1·05–4·42) (0·65–2·56) (0·49–2·35) (0·76–3·92)
IGF-1 > 7·7 nmol/ l 1 1 1 1 1 1 1
Bold text = P < 0·05
*Adjustment for age and sex education, smoking status, alcohol consumption, use of anti-inflammatory drugs (IL-6 and CRP), use of oestrogen (IL-6 and 
CRP), obesity (IL-6 and CRP), physical activity (IL-6 and CRP), season of blood sampling (25(OH)D), PTH (25(OH)D), and the self-reported chronic diseases: 
cardiac disease, peripheral arterial disease, diabetes mellitus, arthritic disease, chronic obstructive pulmonary disease, stroke and cancer.
†Adjustment for all variables mentioned above and number of frailty indicators present at baseline.
Fig. 1 Odds ratios from multinomial logistic analyses of the association 
between 25(OH)D and frailty. The group with 25(OH)D > 50 nmol/ l is the 
reference group. *P < 0·05, **P < 0·01. Adjustment for age, sex, education, 
number of frailty indicators present at baseline, smoking status, alcohol 
consumption, use of anti-inflammatory drugs (IL-6 and CRP), use of 
oestrogen (IL-6 and CRP), obesity (IL-6 and CRP), physical activity (IL-6 
and CRP), season of blood sampling (25(OH)D), PTH (25(OH)D), and the 
following self-reported chronic diseases: cardiac disease, peripheral arterial 
disease, diabetes mellitus, arthritic disease.
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mice against developing insulin-dependent diabetes mellitus.43,44
More research is needed to study the functional relationship between
the endocrine and immune system in humans to gain more insight
into the development of frailty.
In this study and in other studies, a low BMI and a low physical
activity score were used as frailty indicators. The analyses were
adjusted for high-intensity physical activity and a high BMI. This
procedure might have led to over-adjustment, because physical activ-
ity has been shown to be associated with lower inflammation
levels31,34,45 as opposed to obesity, which is associated with greater
inflammation.33 However, the associations did not change when not
adjusting for these factors. Of interest is our finding that those who
were frail at baseline were more often obese than the nonfrail. More-
over, those who became frail were more often obese than those who
did not become frail. These results suggest that the concept of frailty
might need to be adjusted. Possibly, not only low body weight but
also obesity should be included as a frailty indicator. Obesity
increases the risk of arteriosclerosis and cardiovascular disease, both
of which have been suggested as possible pathways leading to frailty.46
The role of the potentially U-shaped relationship between BMI and
frailty should be examined in future studies.
Recent studies showed potential benefit of physical activity with
regard to the levels of inflammatory markers, as physical activity was
associated with lower levels of inflammation.12,34,45 Physical inactivity
is also an important contributor to the development of frailty and
loss of muscle mass. In addition to observational studies, trials are
necessary to investigate the effect of physical activity on inflamma-
tion. So far, to our knowledge, no trials have been performed on the
direct relationship between physical activity and serum inflammatory
markers.
The presence of seven self-reported chronic diseases was studied
as a potential mediator of the relationship between the serum endo-
crine and inflammatory markers and frailty. The chronic diseases
included in this study were chronic obstructive pulmonary disease,
diabetes mellitus, arthritic diseases, peripheral arterial disease, cardiac
diseases, cancer and stroke. These chronic diseases are characterized
by increased inflammation. Chronic diseases are also related to frailty.1
However, no mediating effect of these diseases on the association
between the serum markers and frailty could be demonstrated. This
suggests that the serum markers examined had an independent effect
on prevalent and incident frailty. However, it remains possible that
other chronic diseases, not included in this study, are mediators in
the relationship, leading to an overestimation of the effect of the
serum markers.
A further limitation of this study is the relatively long follow-up
interval of 3 years and the determination of the biological serum
markers at baseline only. Frailty is thought to be a dynamic process
and therefore multiple assessments of frailty and the biological
serum markers using short time intervals might have shown more
precisely the effect of biological serum markers on the development
of frailty.7
In conclusion, this study shows that low serum 25(OH)D concen-
trations are associated with prevalent and incident frailty. The
respondents with moderately elevated serum CRP were at risk of
becoming frail after 3 years. No consistent associations were observed
for IL-6 and IGF-1.
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